United Therapeutics Corporation Q2 2025 Earnings Recap

UTHR Q2 2025 August 1, 2025

United Therapeutics Corporation reported robust earnings with a record revenue of $799 million, marking the 12th consecutive quarter of double-digit growth driven by strong performance from its Tyvaso portfolio and a promising pipeline of innovative therapies.

Earnings Per Share Miss

$6.41 vs $7.29 est.

-12.1% surprise

Revenue Miss

798600000 vs 801868585 est.

-0.4% surprise

Market Reaction

1-Day +7.13%

5-Day +10.09%

30-Day +13.66%

Key Takeaways

Achieved total revenue of $799 million, reflecting a 12% year-over-year increase.
Tyvaso DPI revenues reached a record $315 million, representing 22% growth compared to Q2 2024.
Strong shipment levels for Tyvaso DPI and overall enhanced market dynamics contribute to sustained demand.
Key upcoming clinical milestones include results from TETON 2 and progress in the EXPAND - UKidney study.
Board authorized a share repurchase program of up to $1 billion, reflecting confidence in future growth and shareholder value.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit UTHR on AllInvestView.

Next Q3 2025